Despite new treatment strategies that revolutionized melanoma management and outcomes (e.g. immunotherapy with anti-CTLA-4 or anti-PD-1 antibodies and/or targeted therapy with BRAF or MEK inhibitors), the 5-years survival of melanoma patients remains comprised between 20 and 60% depending on the treatment [1–5]. The gene discussed is CTLA4; the disease is melanoma.